UK markets closed
  • FTSE 100

    6,915.75
    -26.47 (-0.38%)
     
  • FTSE 250

    22,251.26
    +3.72 (+0.02%)
     
  • AIM

    1,236.50
    -2.54 (-0.21%)
     
  • GBP/EUR

    1.1510
    -0.0012 (-0.11%)
     
  • dólar/libra

    1.3706
    -0.0029 (-0.21%)
     
  • BTC-GBP

    44,063.38
    +1,235.23 (+2.88%)
     
  • CMC Crypto 200

    1,235.89
    +8.34 (+0.68%)
     
  • S&P 500

    4,128.80
    +31.63 (+0.77%)
     
  • DOW

    33,800.60
    +297.03 (+0.89%)
     
  • CRUDE OIL

    59.34
    -0.26 (-0.44%)
     
  • GOLD FUTURES

    1,744.10
    -14.10 (-0.80%)
     
  • NIKKEI 225

    29,768.06
    +59.08 (+0.20%)
     
  • HANG SENG

    28,698.80
    -309.27 (-1.07%)
     
  • DAX

    15,234.16
    +31.48 (+0.21%)
     
  • CAC 40

    6,169.41
    +3.69 (+0.06%)
     

Rabies Treatment Market to Reach $5.1 Billion by 2027

ReportLinker
·26-min read

Project Details: - StrategyR - A Trademark of Global Industry Analysts, Inc. - Project Edition: 7. - Influencer Pool: 3381. - MarketGlass™ Platform - Our influencer driven interactive research platform draws from unique perspectives of participating executives from featured companies.

New York, March 31, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Rabies Treatment Industry" - https://www.reportlinker.com/p06043109/?utm_source=GNW
In addition to being a global intelligence exchange platform, MarketGlass™ is a powerful knowledge center that delivers dynamic project-focused market intelligence. Client companies will have complete insider access to the project Data stack.
- Interactive peer-to-peer and enterprise-to-enterprise ideation and market intelligence exchange is facilitated via a robust, secure, and validated process. The process draws from uniquely qualified project-specific and geographically focused executives overseeing business development, marketing and sales operations.

  • Trends & Factors - Identifying and validating local trends and factors driving each competitive marketplace. These factors include pricing variances, market trajectories, Covid-19 impact and recovery, locally active leading brands, and other parameters impacting the region in the short to medium term such as supply chain realignments.

  • Mobile Access & App - Our mobile version of the report may be accessed via our mobile app or directly for a full mobile experience.

  • Complimentary Updates - for one year. At least one update in 12-month period is normal and anytime there’s a significant change affecting the market dynamics.

  • Bespoke Updates & Team Collaborations - Clients may build a bespoke version of our report with peers on our MarketGlass™ platform which enables multidimensional data simulations.

  • Knowledge Center - clients have full-stack data access for project data they support or purchase including primary research engagement stats, companies and executives.

Abstract:
- Global Rabies Treatment Market to Reach $5.1 Billion by 2027
- Amid the COVID-19 crisis, the global market for Rabies Treatment estimated at US$4 Billion in the year 2020, is projected to reach a revised size of US$5.1 Billion by 2027, growing at aCAGR of 3.4% over the period 2020-2027. Post-exposure Prophylaxis, one of the segments analyzed in the report, is projected to record 3.3% CAGR and reach US$3.2 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Pre-exposure Prophylaxis segment is readjusted to a revised 3.8% CAGR for the next 7-year period.
- The U.S. Market is Estimated at $1.1 Billion, While China is Forecast to Grow at 6.3% CAGR
- The Rabies Treatment market in the U.S. is estimated at US$1.1 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.1 Billion by the year 2027 trailing a CAGR of 6.2% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 1% and 2.6% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 1.7% CAGR.

- Select Competitors (Total 46 Featured) -

  • Cadila Healthcare Ltd. (Zydus Cadila)

  • GlaxoSmithKline PLC

  • Merck & Co., Inc.

  • Pfizer, Inc.

  • Sanofi SA




Read the full report: https://www.reportlinker.com/p06043109/?utm_source=GNW

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE
Table 1: World Current & Future Analysis for Rabies Treatment
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 2: World Historic Review for Rabies Treatment by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 3: World 15-Year Perspective for Rabies Treatment by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa Markets for Years 2012, 2020 & 2027

Table 4: World Current & Future Analysis for Post-Exposure
Prophylaxis by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2020 through 2027 and % CAGR

Table 5: World Historic Review for Post-Exposure Prophylaxis by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 6: World 15-Year Perspective for Post-Exposure
Prophylaxis by Geographic Region - Percentage Breakdown of
Value Sales for USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa for Years
2012, 2020 & 2027

Table 7: World Current & Future Analysis for Pre-Exposure
Prophylaxis by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2020 through 2027 and % CAGR

Table 8: World Historic Review for Pre-Exposure Prophylaxis by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 9: World 15-Year Perspective for Pre-Exposure Prophylaxis
by Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

Table 10: World Current & Future Analysis for Cell Culture
Vaccines (CCVs) by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Million for Years 2020 through 2027 and % CAGR

Table 11: World Historic Review for Cell Culture Vaccines
(CCVs) by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 12: World 15-Year Perspective for Cell Culture Vaccines
(CCVs) by Geographic Region - Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific,
Latin America, Middle East and Africa for Years 2012, 2020 &
2027

Table 13: World Current & Future Analysis for Rabies
Immunoglobulin (RIGs) by Geographic Region - USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2020 through 2027 and % CAGR

Table 14: World Historic Review for Rabies Immunoglobulin
(RIGs) by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 15: World 15-Year Perspective for Rabies Immunoglobulin
(RIGs) by Geographic Region - Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific,
Latin America, Middle East and Africa for Years 2012, 2020 &
2027

Table 16: World Current & Future Analysis for Nerve Tissue
Vaccines (NTVs) by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Million for Years 2020 through 2027 and % CAGR

Table 17: World Historic Review for Nerve Tissue Vaccines
(NTVs) by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 18: World 15-Year Perspective for Nerve Tissue Vaccines
(NTVs) by Geographic Region - Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific,
Latin America, Middle East and Africa for Years 2012, 2020 &
2027

III. MARKET ANALYSIS

UNITED STATES
Table 19: USA Current & Future Analysis for Rabies Treatment by
Application - Post-Exposure Prophylaxis and Pre-Exposure
Prophylaxis - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 20: USA Historic Review for Rabies Treatment by
Application - Post-Exposure Prophylaxis and Pre-Exposure
Prophylaxis Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019 and % CAGR

Table 21: USA 15-Year Perspective for Rabies Treatment by
Application - Percentage Breakdown of Value Sales for
Post-Exposure Prophylaxis and Pre-Exposure Prophylaxis for the
Years 2012, 2020 & 2027

Table 22: USA Current & Future Analysis for Rabies Treatment by
Product Type - Cell Culture Vaccines (CCVs), Rabies
Immunoglobulin (RIGs) and Nerve Tissue Vaccines (NTVs) -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 23: USA Historic Review for Rabies Treatment by Product
Type - Cell Culture Vaccines (CCVs), Rabies Immunoglobulin
(RIGs) and Nerve Tissue Vaccines (NTVs) Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 24: USA 15-Year Perspective for Rabies Treatment by
Product Type - Percentage Breakdown of Value Sales for Cell
Culture Vaccines (CCVs), Rabies Immunoglobulin (RIGs) and Nerve
Tissue Vaccines (NTVs) for the Years 2012, 2020 & 2027

CANADA
Table 25: Canada Current & Future Analysis for Rabies Treatment
by Application - Post-Exposure Prophylaxis and Pre-Exposure
Prophylaxis - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 26: Canada Historic Review for Rabies Treatment by
Application - Post-Exposure Prophylaxis and Pre-Exposure
Prophylaxis Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019 and % CAGR

Table 27: Canada 15-Year Perspective for Rabies Treatment by
Application - Percentage Breakdown of Value Sales for
Post-Exposure Prophylaxis and Pre-Exposure Prophylaxis for the
Years 2012, 2020 & 2027

Table 28: Canada Current & Future Analysis for Rabies Treatment
by Product Type - Cell Culture Vaccines (CCVs), Rabies
Immunoglobulin (RIGs) and Nerve Tissue Vaccines (NTVs) -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 29: Canada Historic Review for Rabies Treatment by
Product Type - Cell Culture Vaccines (CCVs), Rabies
Immunoglobulin (RIGs) and Nerve Tissue Vaccines (NTVs) Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 30: Canada 15-Year Perspective for Rabies Treatment by
Product Type - Percentage Breakdown of Value Sales for Cell
Culture Vaccines (CCVs), Rabies Immunoglobulin (RIGs) and Nerve
Tissue Vaccines (NTVs) for the Years 2012, 2020 & 2027

JAPAN
Table 31: Japan Current & Future Analysis for Rabies Treatment
by Application - Post-Exposure Prophylaxis and Pre-Exposure
Prophylaxis - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 32: Japan Historic Review for Rabies Treatment by
Application - Post-Exposure Prophylaxis and Pre-Exposure
Prophylaxis Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019 and % CAGR

Table 33: Japan 15-Year Perspective for Rabies Treatment by
Application - Percentage Breakdown of Value Sales for
Post-Exposure Prophylaxis and Pre-Exposure Prophylaxis for the
Years 2012, 2020 & 2027

Table 34: Japan Current & Future Analysis for Rabies Treatment
by Product Type - Cell Culture Vaccines (CCVs), Rabies
Immunoglobulin (RIGs) and Nerve Tissue Vaccines (NTVs) -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 35: Japan Historic Review for Rabies Treatment by Product
Type - Cell Culture Vaccines (CCVs), Rabies Immunoglobulin
(RIGs) and Nerve Tissue Vaccines (NTVs) Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 36: Japan 15-Year Perspective for Rabies Treatment by
Product Type - Percentage Breakdown of Value Sales for Cell
Culture Vaccines (CCVs), Rabies Immunoglobulin (RIGs) and Nerve
Tissue Vaccines (NTVs) for the Years 2012, 2020 & 2027

CHINA
Table 37: China Current & Future Analysis for Rabies Treatment
by Application - Post-Exposure Prophylaxis and Pre-Exposure
Prophylaxis - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 38: China Historic Review for Rabies Treatment by
Application - Post-Exposure Prophylaxis and Pre-Exposure
Prophylaxis Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019 and % CAGR

Table 39: China 15-Year Perspective for Rabies Treatment by
Application - Percentage Breakdown of Value Sales for
Post-Exposure Prophylaxis and Pre-Exposure Prophylaxis for the
Years 2012, 2020 & 2027

Table 40: China Current & Future Analysis for Rabies Treatment
by Product Type - Cell Culture Vaccines (CCVs), Rabies
Immunoglobulin (RIGs) and Nerve Tissue Vaccines (NTVs) -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 41: China Historic Review for Rabies Treatment by Product
Type - Cell Culture Vaccines (CCVs), Rabies Immunoglobulin
(RIGs) and Nerve Tissue Vaccines (NTVs) Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 42: China 15-Year Perspective for Rabies Treatment by
Product Type - Percentage Breakdown of Value Sales for Cell
Culture Vaccines (CCVs), Rabies Immunoglobulin (RIGs) and Nerve
Tissue Vaccines (NTVs) for the Years 2012, 2020 & 2027

EUROPE
Table 43: Europe Current & Future Analysis for Rabies Treatment
by Geographic Region - France, Germany, Italy, UK, Spain,
Russia and Rest of Europe Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2020 through 2027 and %
CAGR

Table 44: Europe Historic Review for Rabies Treatment by
Geographic Region - France, Germany, Italy, UK, Spain, Russia
and Rest of Europe Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 45: Europe 15-Year Perspective for Rabies Treatment by
Geographic Region - Percentage Breakdown of Value Sales for
France, Germany, Italy, UK, Spain, Russia and Rest of Europe
Markets for Years 2012, 2020 & 2027

Table 46: Europe Current & Future Analysis for Rabies Treatment
by Application - Post-Exposure Prophylaxis and Pre-Exposure
Prophylaxis - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 47: Europe Historic Review for Rabies Treatment by
Application - Post-Exposure Prophylaxis and Pre-Exposure
Prophylaxis Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019 and % CAGR

Table 48: Europe 15-Year Perspective for Rabies Treatment by
Application - Percentage Breakdown of Value Sales for
Post-Exposure Prophylaxis and Pre-Exposure Prophylaxis for the
Years 2012, 2020 & 2027

Table 49: Europe Current & Future Analysis for Rabies Treatment
by Product Type - Cell Culture Vaccines (CCVs), Rabies
Immunoglobulin (RIGs) and Nerve Tissue Vaccines (NTVs) -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 50: Europe Historic Review for Rabies Treatment by
Product Type - Cell Culture Vaccines (CCVs), Rabies
Immunoglobulin (RIGs) and Nerve Tissue Vaccines (NTVs) Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 51: Europe 15-Year Perspective for Rabies Treatment by
Product Type - Percentage Breakdown of Value Sales for Cell
Culture Vaccines (CCVs), Rabies Immunoglobulin (RIGs) and Nerve
Tissue Vaccines (NTVs) for the Years 2012, 2020 & 2027

FRANCE
Table 52: France Current & Future Analysis for Rabies Treatment
by Application - Post-Exposure Prophylaxis and Pre-Exposure
Prophylaxis - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 53: France Historic Review for Rabies Treatment by
Application - Post-Exposure Prophylaxis and Pre-Exposure
Prophylaxis Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019 and % CAGR

Table 54: France 15-Year Perspective for Rabies Treatment by
Application - Percentage Breakdown of Value Sales for
Post-Exposure Prophylaxis and Pre-Exposure Prophylaxis for the
Years 2012, 2020 & 2027

Table 55: France Current & Future Analysis for Rabies Treatment
by Product Type - Cell Culture Vaccines (CCVs), Rabies
Immunoglobulin (RIGs) and Nerve Tissue Vaccines (NTVs) -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 56: France Historic Review for Rabies Treatment by
Product Type - Cell Culture Vaccines (CCVs), Rabies
Immunoglobulin (RIGs) and Nerve Tissue Vaccines (NTVs) Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 57: France 15-Year Perspective for Rabies Treatment by
Product Type - Percentage Breakdown of Value Sales for Cell
Culture Vaccines (CCVs), Rabies Immunoglobulin (RIGs) and Nerve
Tissue Vaccines (NTVs) for the Years 2012, 2020 & 2027

GERMANY
Table 58: Germany Current & Future Analysis for Rabies
Treatment by Application - Post-Exposure Prophylaxis and
Pre-Exposure Prophylaxis - Independent Analysis of Annual Sales
in US$ Million for the Years 2020 through 2027 and % CAGR

Table 59: Germany Historic Review for Rabies Treatment by
Application - Post-Exposure Prophylaxis and Pre-Exposure
Prophylaxis Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019 and % CAGR

Table 60: Germany 15-Year Perspective for Rabies Treatment by
Application - Percentage Breakdown of Value Sales for
Post-Exposure Prophylaxis and Pre-Exposure Prophylaxis for the
Years 2012, 2020 & 2027

Table 61: Germany Current & Future Analysis for Rabies
Treatment by Product Type - Cell Culture Vaccines (CCVs),
Rabies Immunoglobulin (RIGs) and Nerve Tissue Vaccines (NTVs) -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 62: Germany Historic Review for Rabies Treatment by
Product Type - Cell Culture Vaccines (CCVs), Rabies
Immunoglobulin (RIGs) and Nerve Tissue Vaccines (NTVs) Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 63: Germany 15-Year Perspective for Rabies Treatment by
Product Type - Percentage Breakdown of Value Sales for Cell
Culture Vaccines (CCVs), Rabies Immunoglobulin (RIGs) and Nerve
Tissue Vaccines (NTVs) for the Years 2012, 2020 & 2027

ITALY
Table 64: Italy Current & Future Analysis for Rabies Treatment
by Application - Post-Exposure Prophylaxis and Pre-Exposure
Prophylaxis - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 65: Italy Historic Review for Rabies Treatment by
Application - Post-Exposure Prophylaxis and Pre-Exposure
Prophylaxis Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019 and % CAGR

Table 66: Italy 15-Year Perspective for Rabies Treatment by
Application - Percentage Breakdown of Value Sales for
Post-Exposure Prophylaxis and Pre-Exposure Prophylaxis for the
Years 2012, 2020 & 2027

Table 67: Italy Current & Future Analysis for Rabies Treatment
by Product Type - Cell Culture Vaccines (CCVs), Rabies
Immunoglobulin (RIGs) and Nerve Tissue Vaccines (NTVs) -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 68: Italy Historic Review for Rabies Treatment by Product
Type - Cell Culture Vaccines (CCVs), Rabies Immunoglobulin
(RIGs) and Nerve Tissue Vaccines (NTVs) Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 69: Italy 15-Year Perspective for Rabies Treatment by
Product Type - Percentage Breakdown of Value Sales for Cell
Culture Vaccines (CCVs), Rabies Immunoglobulin (RIGs) and Nerve
Tissue Vaccines (NTVs) for the Years 2012, 2020 & 2027

UNITED KINGDOM
Table 70: UK Current & Future Analysis for Rabies Treatment by
Application - Post-Exposure Prophylaxis and Pre-Exposure
Prophylaxis - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 71: UK Historic Review for Rabies Treatment by
Application - Post-Exposure Prophylaxis and Pre-Exposure
Prophylaxis Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019 and % CAGR

Table 72: UK 15-Year Perspective for Rabies Treatment by
Application - Percentage Breakdown of Value Sales for
Post-Exposure Prophylaxis and Pre-Exposure Prophylaxis for the
Years 2012, 2020 & 2027

Table 73: UK Current & Future Analysis for Rabies Treatment by
Product Type - Cell Culture Vaccines (CCVs), Rabies
Immunoglobulin (RIGs) and Nerve Tissue Vaccines (NTVs) -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 74: UK Historic Review for Rabies Treatment by Product
Type - Cell Culture Vaccines (CCVs), Rabies Immunoglobulin
(RIGs) and Nerve Tissue Vaccines (NTVs) Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 75: UK 15-Year Perspective for Rabies Treatment by
Product Type - Percentage Breakdown of Value Sales for Cell
Culture Vaccines (CCVs), Rabies Immunoglobulin (RIGs) and Nerve
Tissue Vaccines (NTVs) for the Years 2012, 2020 & 2027

SPAIN
Table 76: Spain Current & Future Analysis for Rabies Treatment
by Application - Post-Exposure Prophylaxis and Pre-Exposure
Prophylaxis - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 77: Spain Historic Review for Rabies Treatment by
Application - Post-Exposure Prophylaxis and Pre-Exposure
Prophylaxis Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019 and % CAGR

Table 78: Spain 15-Year Perspective for Rabies Treatment by
Application - Percentage Breakdown of Value Sales for
Post-Exposure Prophylaxis and Pre-Exposure Prophylaxis for the
Years 2012, 2020 & 2027

Table 79: Spain Current & Future Analysis for Rabies Treatment
by Product Type - Cell Culture Vaccines (CCVs), Rabies
Immunoglobulin (RIGs) and Nerve Tissue Vaccines (NTVs) -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 80: Spain Historic Review for Rabies Treatment by Product
Type - Cell Culture Vaccines (CCVs), Rabies Immunoglobulin
(RIGs) and Nerve Tissue Vaccines (NTVs) Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 81: Spain 15-Year Perspective for Rabies Treatment by
Product Type - Percentage Breakdown of Value Sales for Cell
Culture Vaccines (CCVs), Rabies Immunoglobulin (RIGs) and Nerve
Tissue Vaccines (NTVs) for the Years 2012, 2020 & 2027

RUSSIA
Table 82: Russia Current & Future Analysis for Rabies Treatment
by Application - Post-Exposure Prophylaxis and Pre-Exposure
Prophylaxis - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 83: Russia Historic Review for Rabies Treatment by
Application - Post-Exposure Prophylaxis and Pre-Exposure
Prophylaxis Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019 and % CAGR

Table 84: Russia 15-Year Perspective for Rabies Treatment by
Application - Percentage Breakdown of Value Sales for
Post-Exposure Prophylaxis and Pre-Exposure Prophylaxis for the
Years 2012, 2020 & 2027

Table 85: Russia Current & Future Analysis for Rabies Treatment
by Product Type - Cell Culture Vaccines (CCVs), Rabies
Immunoglobulin (RIGs) and Nerve Tissue Vaccines (NTVs) -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 86: Russia Historic Review for Rabies Treatment by
Product Type - Cell Culture Vaccines (CCVs), Rabies
Immunoglobulin (RIGs) and Nerve Tissue Vaccines (NTVs) Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 87: Russia 15-Year Perspective for Rabies Treatment by
Product Type - Percentage Breakdown of Value Sales for Cell
Culture Vaccines (CCVs), Rabies Immunoglobulin (RIGs) and Nerve
Tissue Vaccines (NTVs) for the Years 2012, 2020 & 2027

REST OF EUROPE
Table 88: Rest of Europe Current & Future Analysis for Rabies
Treatment by Application - Post-Exposure Prophylaxis and
Pre-Exposure Prophylaxis - Independent Analysis of Annual Sales
in US$ Million for the Years 2020 through 2027 and % CAGR

Table 89: Rest of Europe Historic Review for Rabies Treatment
by Application - Post-Exposure Prophylaxis and Pre-Exposure
Prophylaxis Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019 and % CAGR

Table 90: Rest of Europe 15-Year Perspective for Rabies
Treatment by Application - Percentage Breakdown of Value Sales
for Post-Exposure Prophylaxis and Pre-Exposure Prophylaxis for
the Years 2012, 2020 & 2027

Table 91: Rest of Europe Current & Future Analysis for Rabies
Treatment by Product Type - Cell Culture Vaccines (CCVs),
Rabies Immunoglobulin (RIGs) and Nerve Tissue Vaccines (NTVs) -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 92: Rest of Europe Historic Review for Rabies Treatment
by Product Type - Cell Culture Vaccines (CCVs), Rabies
Immunoglobulin (RIGs) and Nerve Tissue Vaccines (NTVs) Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 93: Rest of Europe 15-Year Perspective for Rabies
Treatment by Product Type - Percentage Breakdown of Value Sales
for Cell Culture Vaccines (CCVs), Rabies Immunoglobulin (RIGs)
and Nerve Tissue Vaccines (NTVs) for the Years 2012, 2020 &
2027

ASIA-PACIFIC
Table 94: Asia-Pacific Current & Future Analysis for Rabies
Treatment by Geographic Region - Australia, India, South Korea
and Rest of Asia-Pacific Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2020 through 2027 and %
CAGR

Table 95: Asia-Pacific Historic Review for Rabies Treatment by
Geographic Region - Australia, India, South Korea and Rest of
Asia-Pacific Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019 and % CAGR

Table 96: Asia-Pacific 15-Year Perspective for Rabies Treatment
by Geographic Region - Percentage Breakdown of Value Sales for
Australia, India, South Korea and Rest of Asia-Pacific Markets
for Years 2012, 2020 & 2027

Table 97: Asia-Pacific Current & Future Analysis for Rabies
Treatment by Application - Post-Exposure Prophylaxis and
Pre-Exposure Prophylaxis - Independent Analysis of Annual Sales
in US$ Million for the Years 2020 through 2027 and % CAGR

Table 98: Asia-Pacific Historic Review for Rabies Treatment by
Application - Post-Exposure Prophylaxis and Pre-Exposure
Prophylaxis Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019 and % CAGR

Table 99: Asia-Pacific 15-Year Perspective for Rabies Treatment
by Application - Percentage Breakdown of Value Sales for
Post-Exposure Prophylaxis and Pre-Exposure Prophylaxis for the
Years 2012, 2020 & 2027

Table 100: Asia-Pacific Current & Future Analysis for Rabies
Treatment by Product Type - Cell Culture Vaccines (CCVs),
Rabies Immunoglobulin (RIGs) and Nerve Tissue Vaccines (NTVs) -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 101: Asia-Pacific Historic Review for Rabies Treatment by
Product Type - Cell Culture Vaccines (CCVs), Rabies
Immunoglobulin (RIGs) and Nerve Tissue Vaccines (NTVs) Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 102: Asia-Pacific 15-Year Perspective for Rabies
Treatment by Product Type - Percentage Breakdown of Value Sales
for Cell Culture Vaccines (CCVs), Rabies Immunoglobulin (RIGs)
and Nerve Tissue Vaccines (NTVs) for the Years 2012, 2020 &
2027

AUSTRALIA
Table 103: Australia Current & Future Analysis for Rabies
Treatment by Application - Post-Exposure Prophylaxis and
Pre-Exposure Prophylaxis - Independent Analysis of Annual Sales
in US$ Million for the Years 2020 through 2027 and % CAGR

Table 104: Australia Historic Review for Rabies Treatment by
Application - Post-Exposure Prophylaxis and Pre-Exposure
Prophylaxis Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019 and % CAGR

Table 105: Australia 15-Year Perspective for Rabies Treatment
by Application - Percentage Breakdown of Value Sales for
Post-Exposure Prophylaxis and Pre-Exposure Prophylaxis for the
Years 2012, 2020 & 2027

Table 106: Australia Current & Future Analysis for Rabies
Treatment by Product Type - Cell Culture Vaccines (CCVs),
Rabies Immunoglobulin (RIGs) and Nerve Tissue Vaccines (NTVs) -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 107: Australia Historic Review for Rabies Treatment by
Product Type - Cell Culture Vaccines (CCVs), Rabies
Immunoglobulin (RIGs) and Nerve Tissue Vaccines (NTVs) Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 108: Australia 15-Year Perspective for Rabies Treatment
by Product Type - Percentage Breakdown of Value Sales for Cell
Culture Vaccines (CCVs), Rabies Immunoglobulin (RIGs) and Nerve
Tissue Vaccines (NTVs) for the Years 2012, 2020 & 2027

INDIA
Table 109: India Current & Future Analysis for Rabies Treatment
by Application - Post-Exposure Prophylaxis and Pre-Exposure
Prophylaxis - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 110: India Historic Review for Rabies Treatment by
Application - Post-Exposure Prophylaxis and Pre-Exposure
Prophylaxis Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019 and % CAGR

Table 111: India 15-Year Perspective for Rabies Treatment by
Application - Percentage Breakdown of Value Sales for
Post-Exposure Prophylaxis and Pre-Exposure Prophylaxis for the
Years 2012, 2020 & 2027

Table 112: India Current & Future Analysis for Rabies Treatment
by Product Type - Cell Culture Vaccines (CCVs), Rabies
Immunoglobulin (RIGs) and Nerve Tissue Vaccines (NTVs) -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 113: India Historic Review for Rabies Treatment by
Product Type - Cell Culture Vaccines (CCVs), Rabies
Immunoglobulin (RIGs) and Nerve Tissue Vaccines (NTVs) Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 114: India 15-Year Perspective for Rabies Treatment by
Product Type - Percentage Breakdown of Value Sales for Cell
Culture Vaccines (CCVs), Rabies Immunoglobulin (RIGs) and Nerve
Tissue Vaccines (NTVs) for the Years 2012, 2020 & 2027

SOUTH KOREA
Table 115: South Korea Current & Future Analysis for Rabies
Treatment by Application - Post-Exposure Prophylaxis and
Pre-Exposure Prophylaxis - Independent Analysis of Annual Sales
in US$ Million for the Years 2020 through 2027 and % CAGR

Table 116: South Korea Historic Review for Rabies Treatment by
Application - Post-Exposure Prophylaxis and Pre-Exposure
Prophylaxis Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019 and % CAGR

Table 117: South Korea 15-Year Perspective for Rabies Treatment
by Application - Percentage Breakdown of Value Sales for
Post-Exposure Prophylaxis and Pre-Exposure Prophylaxis for the
Years 2012, 2020 & 2027

Table 118: South Korea Current & Future Analysis for Rabies
Treatment by Product Type - Cell Culture Vaccines (CCVs),
Rabies Immunoglobulin (RIGs) and Nerve Tissue Vaccines (NTVs) -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 119: South Korea Historic Review for Rabies Treatment by
Product Type - Cell Culture Vaccines (CCVs), Rabies
Immunoglobulin (RIGs) and Nerve Tissue Vaccines (NTVs) Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 120: South Korea 15-Year Perspective for Rabies Treatment
by Product Type - Percentage Breakdown of Value Sales for Cell
Culture Vaccines (CCVs), Rabies Immunoglobulin (RIGs) and Nerve
Tissue Vaccines (NTVs) for the Years 2012, 2020 & 2027

REST OF ASIA-PACIFIC
Table 121: Rest of Asia-Pacific Current & Future Analysis for
Rabies Treatment by Application - Post-Exposure Prophylaxis and
Pre-Exposure Prophylaxis - Independent Analysis of Annual Sales
in US$ Million for the Years 2020 through 2027 and % CAGR

Table 122: Rest of Asia-Pacific Historic Review for Rabies
Treatment by Application - Post-Exposure Prophylaxis and
Pre-Exposure Prophylaxis Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR

Table 123: Rest of Asia-Pacific 15-Year Perspective for Rabies
Treatment by Application - Percentage Breakdown of Value Sales
for Post-Exposure Prophylaxis and Pre-Exposure Prophylaxis for
the Years 2012, 2020 & 2027

Table 124: Rest of Asia-Pacific Current & Future Analysis for
Rabies Treatment by Product Type - Cell Culture Vaccines
(CCVs), Rabies Immunoglobulin (RIGs) and Nerve Tissue Vaccines
(NTVs) - Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027 and % CAGR

Table 125: Rest of Asia-Pacific Historic Review for Rabies
Treatment by Product Type - Cell Culture Vaccines (CCVs),
Rabies Immunoglobulin (RIGs) and Nerve Tissue Vaccines (NTVs)
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 126: Rest of Asia-Pacific 15-Year Perspective for Rabies
Treatment by Product Type - Percentage Breakdown of Value Sales
for Cell Culture Vaccines (CCVs), Rabies Immunoglobulin (RIGs)
and Nerve Tissue Vaccines (NTVs) for the Years 2012, 2020 &
2027

LATIN AMERICA
Table 127: Latin America Current & Future Analysis for Rabies
Treatment by Geographic Region - Argentina, Brazil, Mexico and

Please contact our Customer Support Center to get the complete Table of Contents
Read the full report: https://www.reportlinker.com/p06043109/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001